David J. Gury
Direktor/Vorstandsmitglied bei Scripps Florida Funding Corp.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jennifer O'Flannery Anderson | M | - |
Florida Atlantic University Foundation, Inc.
| - |
| Patricia A. McKay | F | 66 |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| Thomas Workman | M | - |
Florida Atlantic University Foundation, Inc.
| - |
| Michael Miller | M | - |
Florida Atlantic University Foundation, Inc.
| 6 Jahre |
| Pamella Dana | M | 61 |
Scripps Florida Funding Corp.
| 17 Jahre |
| Noel Gonzalez | M | - |
Florida Atlantic University Foundation, Inc.
| 1 Jahre |
| Marilyn Weinberg | F | - |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| Stewart Martin | M | 59 |
Florida Atlantic University Foundation, Inc.
| 14 Jahre |
| Bonnie Kaye | F | - |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| Dale Gregory | M | - |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| Brett Greenberg | M | - |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| John L. Duffy | M | - |
Florida Atlantic University Foundation, Inc.
| - |
| James L. Seitz | M | - |
Florida Atlantic University Foundation, Inc.
| - |
| T. Crook | M | 73 |
Scripps Florida Funding Corp.
| - |
| Ayden Maher | M | - |
Florida Atlantic University Foundation, Inc.
| - |
| Marleen Forkas | F | - |
Florida Atlantic University Foundation, Inc.
| - |
| Kathleen Grace | F | - |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| Ira J. Gelb | M | - |
Florida Atlantic University Foundation, Inc.
| - |
| Robert K. Rollins | M | - |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| William S. Bernstein | M | - |
Florida Atlantic University Foundation, Inc.
| - |
| Denise Dickins | M | 62 |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| Frederick V. Miller | M | 68 |
Florida Atlantic University Foundation, Inc.
| - |
| Jay M. Weinberg | M | 91 |
Florida Atlantic University Foundation, Inc.
| 12 Jahre |
| Bill Foley | M | 79 |
Scripps Florida Funding Corp.
| - |
| Ruben Jose King-Shaw | M | 63 |
Scripps Florida Funding Corp.
| - |
| Richard Luceri | M | - |
Scripps Florida Funding Corp.
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Peggy A. Farley | F | 77 | 3 Jahre | |
| Raafat E. F. Fahim | M | 70 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 9 Jahre |
| Paul A. Hassie | M | - | - | |
| Thomas McLain | M | 66 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 9 Jahre |
| Karl E. Groth | M | 76 | 1 Jahre | |
| Adam Logal | M | 46 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 5 Jahre |
| Mark L. Smith | M | 72 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 Jahre |
| Richard A. Harvey | M | 74 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 20 Jahre |
| Geoffrey F. Cox | M | 80 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 12 Jahre |
| David L. Castaldi | M | 84 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 18 Jahre |
| Dorothy Jean Delfino | F | 78 | 2 Jahre | |
| Lorraine M. Breece | F | 71 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 8 Jahre |
| Kevin H. Sills | M | - | - | |
| Matthew J. Fendrich | M | 57 | - | |
| Richard T. Welch | M | 72 | 2 Jahre | |
| Thomas Spitznagel | M | 57 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 2 Jahre |
| Ronald P. Evens | M | - | - | |
| Angel R. Rodriguez | M | - | - | |
| Richard T. Spencer | M | - | - | |
| Samuel S. Ahn | M | 69 | 7 Jahre | |
| George T. Hawes | M | 77 | 2 Jahre | |
| Stanley B. Stein | M | 71 | 1 Jahre | |
| Eric Chojnicki | M | - | - | |
| Nicholas M. Burke | M | 52 | 2 Jahre | |
| Mento A. Soponis | M | - | - | |
| Brian Anderson | M | 77 | - | |
| Stephen G. Sudovar | M | 77 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 8 Jahre |
| Alan P. Timmins | M | 63 | 1 Jahre | |
| Linda S. Jenckes | F | 76 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 13 Jahre |
| Derek Hennecke | M | - | 1 Jahre | |
| William Pinon | M | 60 | 1 Jahre | |
| William H. Kline | M | 79 | 3 Jahre | |
| Daniel E. Greenleaf | M | 59 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 1 Jahre |
| Linda Palermo | F | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 60 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David J. Gury
- Persönliches Netzwerk
